The stock of Xenon Pharmaceuticals Inc (NASDAQ: XENE) has increased by 1.67 when compared to last closing price of 32.26. Despite this, the company has experienced a 6.74% gain in its stock price over the last five trading sessions. zacks.com reported 2025-06-11 that Xenon Pharmaceuticals (XENE) reported earnings 30 days ago. What’s next for the stock?
Is It Worth Investing in Xenon Pharmaceuticals Inc (NASDAQ: XENE) Right Now?
The stock has a 36-month beta value of 1.10. Opinions on the stock are mixed, with 14 analysts rating it as a “buy,” 5 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for XENE is 74.39M, and at present, short sellers hold a 4.53% of that float. On June 13, 2025, the average trading volume of XENE was 980.06K shares.
XENE’s Market Performance
XENE stock saw an increase of 6.74% in the past week, with a monthly gain of 10.81% and a quarterly increase of -6.77%. The volatility ratio for the week is 1.29%, and the volatility levels for the last 30 days are 2.06% for Xenon Pharmaceuticals Inc (XENE). The simple moving average for the past 20 days is 7.35% for XENE’s stock, with a -13.54% simple moving average for the past 200 days.
Analysts’ Opinion of XENE
Many brokerage firms have already submitted their reports for XENE stocks, with Chardan Capital Markets repeating the rating for XENE by listing it as a “Buy.” The predicted price for XENE in the upcoming period, according to Chardan Capital Markets is $55 based on the research report published on May 07, 2025 of the current year 2025.
Deutsche Bank, on the other hand, stated in their research note that they expect to see XENE reach a price target of $67. The rating they have provided for XENE stocks is “Buy” according to the report published on February 11th, 2025.
Raymond James gave a rating of “Outperform” to XENE, setting the target price at $50 in the report published on October 10th of the previous year.
XENE Trading at -0.00% from the 50-Day Moving Average
After a stumble in the market that brought XENE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -28.70% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at XENE starting from GANNON STEVEN, who sale 3 shares at the price of $30.48 back on Jun 05 ’25. After this action, GANNON STEVEN now owns 7,141 shares of Xenon Pharmaceuticals Inc, valued at $91 using the latest closing price.
MORTIMER IAN, the PRESIDENT & CEO of Xenon Pharmaceuticals Inc, sale 22,468 shares at $40.20 during a trade that took place back on Jan 24 ’25, which means that MORTIMER IAN is holding 31,302 shares at $903,214 based on the most recent closing price.
Stock Fundamentals for XENE
Current profitability levels for the company are sitting at:
- -39.07 for the present operating margin
- -0.09 for the gross margin
The net margin for Xenon Pharmaceuticals Inc stands at -33.53. The total capital return value is set at -0.4. Equity return is now at value -31.60, with -30.25 for asset returns.
Based on Xenon Pharmaceuticals Inc (XENE), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -23.04.
Currently, EBITDA for the company is -235.86 million with net debt to EBITDA at 0.37. When we switch over and look at the enterprise to sales, we see a ratio of 321.18. The receivables turnover for the company is 0.87for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 17.66.
Conclusion
To sum up, Xenon Pharmaceuticals Inc (XENE) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
